AI-generated analysis. Always verify with the original filing.
Pelthos Therapeutics Inc. announced fourth quarter and full year 2025 financial results via press release, reporting ZELSUVMI net product revenue of $9.1 million in Q4 (28% increase from Q3) and $16.2 million since July 2025 launch, with total 2025 revenue of $16.8 million. Highlights include acquisitions of XEPI in November 2025 and XEGLYZE in January 2026, $18 million convertible notes financing, and $30 million term loan draw.
Event Type
Disclosure
Mandatory
Variant
8-K
and Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, o
and Exhibit 99.2 attached hereto shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required t
. Financial Statements and Exhibits (d) Exhibits: Exhibit No. Description 99.1 Press Release, dated March 19, 2026 99.2 Company Presentation 104 Cover Page Inte
| Metric | Value | Basis |
|---|---|---|
| Net product revenues | $9.1K | GAAP |
| Total revenue | $9.4K | GAAP |
| Operating loss | $-12.0K | GAAP |
| Net loss | $-21.7K | GAAP |
| Net loss per common share - basic and diluted | $-6.87 | GAAP |
| Full year net product revenues | $16.2K | GAAP |
| Full year total revenue | $16.8K | GAAP |
| Full year net loss | $-43.3K | GAAP |
| Full year net loss per common share - basic and diluted | $-23.04 | GAAP |